A simple blood draw can provide physicians with valuable information that can determine if peptide receptor radionuclide therapy (PRRT) is likely to be effective in a patient with neuroendocrine ...
Since its approval in 2018 by the US Food and Drug Administration, peptide receptor radionuclide therapy (PRRT) has become a mainstay in the treatment of neuroendocrine tumors. Lutetium-177-DOTATATE, ...
Combination of ZG005 with etoposide and cisplatin (EP) vs. EP as the first-line therapy for advanced neuroendocrine carcinoma: A randomized, multicenter, phase I/II trial. This is an ASCO Meeting ...
Reston, VA—Peptide receptor radionuclide therapy (PRRT) is effective for clinical control of symptomatic metastatic insulinomas, according to new research published in the February issue of The ...
Transaxial slices of baseline positron emission tomography (PET) and fused PET/magnetic resonance imaging (MRI; left) demonstrate a somatostatin receptor-expressing meningioma in the left cavernous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results